Vanda Pharmaceuticals (FRA:VM4) Tariff Resilience Score: 8/10 (As of Jun. 24, 2026)


FRA:VM4 Vanda Pharmaceuticals Inc FRA:VM4
75 GF Score
Price €5.10
GF Value €4.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Tariff Resilience Score?

Vanda Pharmaceuticals FRA:VM4 +4.94% 75 Tariff Resilience Score is 8 as of Jun. 24, 2026. GuruFocus rates FRA:VM4 with a GF Score™ of 75/100 and a GF Value™ of €4.70 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,379 Biotechnology companies, Vanda Pharmaceuticals ranks better than 98.69% on this metric.

Vanda Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Vanda Pharmaceuticals has Vanda Pharmaceuticals Inc is resilient to tariffs due to its focus on domestic manufacturing and sales. The company has minimal exposure to international supply chains and has not been significantly impacted by past tariff changes, with strong pricing power as a mitigation strategy.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vanda Pharmaceuticals might have Highly Resilient.

Vanda Pharmaceuticals  (FRA:VM4) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vanda Pharmaceuticals Tariff Resilience Score Related Terms

FRA:VM4 vs FBRX, ARTV, OABI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanda Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Tariff Resilience Score falls into.


FRA:VM4
75GF Score
Vanda Pharmaceuticals Inc FRA:VM4
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Vanda Pharmaceuticals (FRA:VM4) has a Tariff Resilience Score of 8 as of Jun. 24, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vanda Pharmaceuticals ranks #18 out of 1379 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Vanda Pharmaceuticals' Tariff Resilience Score too high?
Vanda Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Vanda Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Vanda Pharmaceuticals ranks #18 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vanda Pharmaceuticals has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Tariff Resilience Score compare to FBRX and ARTV?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #18 out of 1379 companies for Tariff Resilience Score. This places Vanda Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Vanda Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanda Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanda Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (FRA:VM4) is currently considered Fairly Valued. The stock's GF Value™ is €4.70, compared to a current price of €5.10 — trading 8.5% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Vanda Pharmaceuticals' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vanda Pharmaceuticals (FRA:VM4), the current Tariff Resilience Score is 8 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (FRA:VM4) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of €5.10 is trading 8.5% above its estimated GF Value™ of €4.70. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:VM4:

  • Tariff Resilience Score: 8
  • GF Value™: €4.70 vs. price of €5.10 (8.5% above fair value)
  • GF Score™: 75/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1379)

No single metric tells the full story. See the FRA:VM4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USA0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score

Get the complete analysis for FRA:VM4

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.10
Price
€4.70
GF Value